January 25, 2021
Theranica, an Israeli prescription digital therapeutics developer for migraine and other pain conditions, has received 510(k) clearance from the U.S. Food and Drug Administration for its Nerivio device.
The device has been cleared for acute treatment of episodic or chronic migraine in people 12 years and older.
Nerivio is a wireless, noninvasive remote electrical-stimulation wearable that is worn...
September 1, 2020
Nurx, a women’s health platform best known for using telemedicine to connect patients with contraceptives and STI testing, is dipping into the migraine space. Today it launched a new service that lets patients virtually connect with a provider and develop an individualized migraine management plan.
Patients pay a $60 annual fee, which includes online medical consultations, a video exam where...
Above: Alon Ironi, CEO & Co-Founder, Theranica. Credit: Theranica
June 16, 2019
Pain is usually an indication something wrong with the body and the typical approach to pain is to take appropriate medicine that will help alleviate that pain. However, taking painkillers will have some side effects and it is more complicated, or even life-threatening for those who are allergic to certain painkillers.
Imagine a future where pain can be managed or alleviated using a combination...
An illustrated graphic of how the Nerivio Migra device works. Source: Theranica
May 28, 2019
Theranica, an Israel-based biomedical technology company focused on developing advanced electroceuticals for migraine and other prevalent diseases, announced on May 28 that the U.S. Food and Drug Administration (FDA) granted a De Novo request for its smartphone-controlled electroceutical, Nerivio Migra, utilising Remote Electrical Neuromodulation for the acute treatment of migraine.
An illustrated graphic of how the Nerivio Migra® device works. Source: Theranica
March 19, 2019
Founded in 2016, Theranica, a biomedical technology company focused on developing advanced electroceuticals for migraine and other prevalent diseases, yesterday announced the closing of its round B of financing, of $35M, led by aMoon, Israel's largest healthcare VC. All existing investors of the company – Lightspeed Venture Partners, LionBird, Corundum Open Innovation and Takoa – participated in...
August 30, 2018
A recent presentation by headache-focused digital health company Healint and pharma giant Novartis employed Healint’s migraine tracking app Migraine Buddy to look at how migraines interact with anxiety and depression. The research found that chronic migraines may induce anxiety and depression instead of the other way around, contradicting previous thought.
Researchers were able to look at the...
October 30, 2017
Mountain View, California-based Second Opinion Health is seeing strong feedback since recently exiting stealth mode for release of its first product Migraine Alert, an app that provides personalized predictions of migraine episodes for people with intermittent migraines. The company's app, currently being offered direct to consumers, is being studied at the Mayo Clinic in trials backed by...